Compare CFFI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | ENTA |
|---|---|---|
| Founded | 1927 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.3M | 339.0M |
| IPO Year | 1996 | 2012 |
| Metric | CFFI | ENTA |
|---|---|---|
| Price | $109.74 | $11.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.83 |
| AVG Volume (30 Days) | 51.1K | ★ 251.0K |
| Earning Date | 10-26-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 37.94 | 29.93 |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $140,841,000.00 | $102,814,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | $23.23 | ★ N/A |
| Revenue Growth | 10.63 | ★ 16.48 |
| 52 Week Low | $66.48 | $10.22 |
| 52 Week High | $110.52 | $17.15 |
| Indicator | CFFI | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 72.87 | 40.79 |
| Support Level | $70.30 | $10.90 |
| Resistance Level | N/A | $13.94 |
| Average True Range (ATR) | 2.80 | 0.66 |
| MACD | 0.35 | 0.02 |
| Stochastic Oscillator | 78.80 | 25.19 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.